Novel Rx
David Liew drdavidliew
3 years 10 months ago
Despite >20y of bDMARDs, our patients still have a 50% greater risk of cardiovascular issues
(similar to family history or abdominal obesity)
Cardiovascular disease in RA is not historic, it's today's reality we too often ignore.
2020 data @VUamsterdam #ACR21 ABST0286 @RheumNow https://t.co/Az4wHNUOGe
David Liew drdavidliew
3 years 10 months ago
PsA bDMARD use in Australia🇦🇺
(where once you qualify for a bDMARD in general, it's the physician's free choice)
1. cool Sankey diagram showing switches
2. given the chance, people switch in all directions & switch hard
(registry linked with insurance)
#ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 10 months ago
Abst#0268
➡️Do lipids change w/ some bDMARDs in RA? YES!
⭐︎ TCZ: ↑ TC, LDL, TG & ↓ in hsCRP relative to initiating TNFi.
➡️Does this lipid ↑ confer risk for CVD? Not necessarily as it may not be atherogenic per Reynolds Risk Score!
#ACR21 @Rheumnow
https://t.co/Gy62mg6GhZ https://t.co/5uC8Zy0Lbr
Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Aurinia
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine (
Poster Hall